Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU®-Multi-HIVB, in untreated HIV-1 infected subjects
► FIT GTU®-multi-HIVB was the first therapeutic HIV-1 vaccine trial conducted in South Africa. ► This plasmid DNA vaccine is safe and well-tolerated in HIV-1 infected, anteretrovial naive subjects. ► Cross subtype reactivity of subtype B derived vaccine in subtype C infected subjects was shown. ► Si...
Saved in:
| Published in | Vaccine Vol. 30; no. 27; pp. 4046 - 4054 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
08.06.2012
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2012.04.007 |
Cover
| Abstract | ► FIT GTU®-multi-HIVB was the first therapeutic HIV-1 vaccine trial conducted in South Africa. ► This plasmid DNA vaccine is safe and well-tolerated in HIV-1 infected, anteretrovial naive subjects. ► Cross subtype reactivity of subtype B derived vaccine in subtype C infected subjects was shown. ► Significant CD4 increases and VL decreases after IM vaccine were maintained for more than 2 years. ► This DNA HIV vaccine may be used as affordable prime/boost regimens alone or as an adjunct to HAART.
Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the search for simpler, affordable HIV-1 treatment modalities. Therapeutic HIV-1 vaccines aim to provide immunological support to slow disease progression and decrease transmission. We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU®-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate.
63 untreated, healthy, HIV-1 infected, adults between 18 and 40 years were enrolled in a single-blinded, placebo-controlled Phase II trial in South Africa. Subjects were HIV-1 subtype C infected, had never received antiretrovirals, with CD4≥350cells/mm3 and pHIV-RNA≥50copies/mL at screening. Subjects were allocated to vaccine or placebo groups in a 2:1 ratio either administered intradermally (ID) (0.5mg/dose) or intramuscularly (IM) (1mg/dose) at 0, 4 and 12 weeks boosted at 76 and 80 weeks with 1mg/dose (ID) and 2mg/dose (IM), respectively. Safety was assessed by adverse event monitoring and immunogenicity by HIV-1-specific CD4+ and CD8+ T-cells using intracellular cytokine staining (ICS), pHIV-RNA and CD4 counts.
Vaccine was safe and well tolerated with no vaccine related serious adverse events. Significant declines in logpHIV-RNA (p=0.012) and increases in CD4+ T cell counts (p=0.066) were observed in the vaccine group compared to placebo, more pronounced after IM administration and in some HLA haplotypes (B*5703) maintained for 17 months after the final immunisation.
The GTU®-multi-HIVB plasmid recombinant DNA therapeutic HIV-1 vaccine is safe, well tolerated and favourably affects pHIV-RNA and CD4 counts in untreated HIV-1infected individuals after IM administration in subjects with HLA B*57, B*8101 and B*5801haplotypes. |
|---|---|
| AbstractList | Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the search for simpler, affordable HIV-1 treatment modalities. Therapeutic HIV-1 vaccines aim to provide immunological support to slow disease progression and decrease transmission. We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU(®)-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate.
63 untreated, healthy, HIV-1 infected, adults between 18 and 40 years were enrolled in a single-blinded, placebo-controlled Phase II trial in South Africa. Subjects were HIV-1 subtype C infected, had never received antiretrovirals, with CD4 ≥ 350 cells/mm(3) and pHIV-RNA ≥ 50 copies/mL at screening. Subjects were allocated to vaccine or placebo groups in a 2:1 ratio either administered intradermally (ID) (0.5mg/dose) or intramuscularly (IM) (1mg/dose) at 0, 4 and 12 weeks boosted at 76 and 80 weeks with 1mg/dose (ID) and 2mg/dose (IM), respectively. Safety was assessed by adverse event monitoring and immunogenicity by HIV-1-specific CD4+ and CD8+ T-cells using intracellular cytokine staining (ICS), pHIV-RNA and CD4 counts.
Vaccine was safe and well tolerated with no vaccine related serious adverse events. Significant declines in log pHIV-RNA (p=0.012) and increases in CD4+ T cell counts (p=0.066) were observed in the vaccine group compared to placebo, more pronounced after IM administration and in some HLA haplotypes (B*5703) maintained for 17 months after the final immunisation.
The GTU(®)-multi-HIVB plasmid recombinant DNA therapeutic HIV-1 vaccine is safe, well tolerated and favourably affects pHIV-RNA and CD4 counts in untreated HIV-1 infected individuals after IM administration in subjects with HLA B*57, B*8101 and B*5801 haplotypes. BACKGROUND: Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the search for simpler, affordable HIV-1 treatment modalities. Therapeutic HIV-1 vaccines aim to provide immunological support to slow disease progression and decrease transmission. We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU®-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate. METHODS: 63 untreated, healthy, HIV-1 infected, adults between 18 and 40 years were enrolled in a single-blinded, placebo-controlled Phase II trial in South Africa. Subjects were HIV-1 subtype C infected, had never received antiretrovirals, with CD4≥350cells/mm³ and pHIV-RNA≥50copies/mL at screening. Subjects were allocated to vaccine or placebo groups in a 2:1 ratio either administered intradermally (ID) (0.5mg/dose) or intramuscularly (IM) (1mg/dose) at 0, 4 and 12 weeks boosted at 76 and 80 weeks with 1mg/dose (ID) and 2mg/dose (IM), respectively. Safety was assessed by adverse event monitoring and immunogenicity by HIV-1-specific CD4+ and CD8+ T-cells using intracellular cytokine staining (ICS), pHIV-RNA and CD4 counts. RESULTS: Vaccine was safe and well tolerated with no vaccine related serious adverse events. Significant declines in logpHIV-RNA (p=0.012) and increases in CD4+ T cell counts (p=0.066) were observed in the vaccine group compared to placebo, more pronounced after IM administration and in some HLA haplotypes (B*5703) maintained for 17 months after the final immunisation. CONCLUSIONS: The GTU®-multi-HIVB plasmid recombinant DNA therapeutic HIV-1 vaccine is safe, well tolerated and favourably affects pHIV-RNA and CD4 counts in untreated HIV-1infected individuals after IM administration in subjects with HLA B*57, B*8101 and B*5801haplotypes. Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the search for simpler, affordable HIV-1 treatment modalities. Therapeutic HIV-1 vaccines aim to provide immunological support to slow disease progression and decrease transmission. We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU(®)-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate.BACKGROUNDCombination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the search for simpler, affordable HIV-1 treatment modalities. Therapeutic HIV-1 vaccines aim to provide immunological support to slow disease progression and decrease transmission. We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU(®)-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate.63 untreated, healthy, HIV-1 infected, adults between 18 and 40 years were enrolled in a single-blinded, placebo-controlled Phase II trial in South Africa. Subjects were HIV-1 subtype C infected, had never received antiretrovirals, with CD4 ≥ 350 cells/mm(3) and pHIV-RNA ≥ 50 copies/mL at screening. Subjects were allocated to vaccine or placebo groups in a 2:1 ratio either administered intradermally (ID) (0.5mg/dose) or intramuscularly (IM) (1mg/dose) at 0, 4 and 12 weeks boosted at 76 and 80 weeks with 1mg/dose (ID) and 2mg/dose (IM), respectively. Safety was assessed by adverse event monitoring and immunogenicity by HIV-1-specific CD4+ and CD8+ T-cells using intracellular cytokine staining (ICS), pHIV-RNA and CD4 counts.METHODS63 untreated, healthy, HIV-1 infected, adults between 18 and 40 years were enrolled in a single-blinded, placebo-controlled Phase II trial in South Africa. Subjects were HIV-1 subtype C infected, had never received antiretrovirals, with CD4 ≥ 350 cells/mm(3) and pHIV-RNA ≥ 50 copies/mL at screening. Subjects were allocated to vaccine or placebo groups in a 2:1 ratio either administered intradermally (ID) (0.5mg/dose) or intramuscularly (IM) (1mg/dose) at 0, 4 and 12 weeks boosted at 76 and 80 weeks with 1mg/dose (ID) and 2mg/dose (IM), respectively. Safety was assessed by adverse event monitoring and immunogenicity by HIV-1-specific CD4+ and CD8+ T-cells using intracellular cytokine staining (ICS), pHIV-RNA and CD4 counts.Vaccine was safe and well tolerated with no vaccine related serious adverse events. Significant declines in log pHIV-RNA (p=0.012) and increases in CD4+ T cell counts (p=0.066) were observed in the vaccine group compared to placebo, more pronounced after IM administration and in some HLA haplotypes (B*5703) maintained for 17 months after the final immunisation.RESULTSVaccine was safe and well tolerated with no vaccine related serious adverse events. Significant declines in log pHIV-RNA (p=0.012) and increases in CD4+ T cell counts (p=0.066) were observed in the vaccine group compared to placebo, more pronounced after IM administration and in some HLA haplotypes (B*5703) maintained for 17 months after the final immunisation.The GTU(®)-multi-HIVB plasmid recombinant DNA therapeutic HIV-1 vaccine is safe, well tolerated and favourably affects pHIV-RNA and CD4 counts in untreated HIV-1 infected individuals after IM administration in subjects with HLA B*57, B*8101 and B*5801 haplotypes.CONCLUSIONSThe GTU(®)-multi-HIVB plasmid recombinant DNA therapeutic HIV-1 vaccine is safe, well tolerated and favourably affects pHIV-RNA and CD4 counts in untreated HIV-1 infected individuals after IM administration in subjects with HLA B*57, B*8101 and B*5801 haplotypes. Highlights► FIT GTU ®-multi-HIVB was the first therapeutic HIV-1 vaccine trial conducted in South Africa. ► This plasmid DNA vaccine is safe and well-tolerated in HIV-1 infected, anteretrovial naive subjects. ► Cross subtype reactivity of subtype B derived vaccine in subtype C infected subjects was shown. ► Significant CD4 increases and VL decreases after IM vaccine were maintained for more than 2 years. ► This DNA HIV vaccine may be used as affordable prime/boost regimens alone or as an adjunct to HAART. Highlights * FIT GTU®-multi-HIVB was the first therapeutic HIV-1 vaccine trial conducted in South Africa. * This plasmid DNA vaccine is safe and well-tolerated in HIV-1 infected, anteretrovial naive subjects. * Cross subtype reactivity of subtype B derived vaccine in subtype C infected subjects was shown. * Significant CD4 increases and VL decreases after IM vaccine were maintained for more than 2 years. * This DNA HIV vaccine may be used as affordable prime/boost regimens alone or as an adjunct to HAART. ► FIT GTU®-multi-HIVB was the first therapeutic HIV-1 vaccine trial conducted in South Africa. ► This plasmid DNA vaccine is safe and well-tolerated in HIV-1 infected, anteretrovial naive subjects. ► Cross subtype reactivity of subtype B derived vaccine in subtype C infected subjects was shown. ► Significant CD4 increases and VL decreases after IM vaccine were maintained for more than 2 years. ► This DNA HIV vaccine may be used as affordable prime/boost regimens alone or as an adjunct to HAART. Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the search for simpler, affordable HIV-1 treatment modalities. Therapeutic HIV-1 vaccines aim to provide immunological support to slow disease progression and decrease transmission. We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU®-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate. 63 untreated, healthy, HIV-1 infected, adults between 18 and 40 years were enrolled in a single-blinded, placebo-controlled Phase II trial in South Africa. Subjects were HIV-1 subtype C infected, had never received antiretrovirals, with CD4≥350cells/mm3 and pHIV-RNA≥50copies/mL at screening. Subjects were allocated to vaccine or placebo groups in a 2:1 ratio either administered intradermally (ID) (0.5mg/dose) or intramuscularly (IM) (1mg/dose) at 0, 4 and 12 weeks boosted at 76 and 80 weeks with 1mg/dose (ID) and 2mg/dose (IM), respectively. Safety was assessed by adverse event monitoring and immunogenicity by HIV-1-specific CD4+ and CD8+ T-cells using intracellular cytokine staining (ICS), pHIV-RNA and CD4 counts. Vaccine was safe and well tolerated with no vaccine related serious adverse events. Significant declines in logpHIV-RNA (p=0.012) and increases in CD4+ T cell counts (p=0.066) were observed in the vaccine group compared to placebo, more pronounced after IM administration and in some HLA haplotypes (B*5703) maintained for 17 months after the final immunisation. The GTU®-multi-HIVB plasmid recombinant DNA therapeutic HIV-1 vaccine is safe, well tolerated and favourably affects pHIV-RNA and CD4 counts in untreated HIV-1infected individuals after IM administration in subjects with HLA B*57, B*8101 and B*5801haplotypes. |
| Author | Stanescu, Ioana Vardas, Eftyhia Leinonen, Mika Pantaleo, Giuseppe Ustav, Mart Valtavaara, Minna Ellefsen, Kim Reijonen, Kalevi |
| Author_xml | – sequence: 1 givenname: Eftyhia surname: Vardas fullname: Vardas, Eftyhia email: eftyxia.vardas@lancet.co.za, vardas@sun.ac.za organization: Lancet Laboratories, Richmond, Johannesburg, South Africa – sequence: 2 givenname: Ioana surname: Stanescu fullname: Stanescu, Ioana organization: FIT Biotech Ltd., Tampere, Finland – sequence: 3 givenname: Mika surname: Leinonen fullname: Leinonen, Mika organization: 4 Pharma Ltd., Turku, Finland – sequence: 4 givenname: Kim surname: Ellefsen fullname: Ellefsen, Kim organization: Centre Hospitalier Universitaire Vaudois, CH - 1011 Lausanne, Switzerland – sequence: 5 givenname: Giuseppe surname: Pantaleo fullname: Pantaleo, Giuseppe organization: Centre Hospitalier Universitaire Vaudois, CH - 1011 Lausanne, Switzerland – sequence: 6 givenname: Minna surname: Valtavaara fullname: Valtavaara, Minna organization: FIT Biotech Ltd., Tampere, Finland – sequence: 7 givenname: Mart surname: Ustav fullname: Ustav, Mart organization: FIT Biotech Ltd., Tartu, Estonia – sequence: 8 givenname: Kalevi surname: Reijonen fullname: Reijonen, Kalevi organization: FIT Biotech Ltd., Tampere, Finland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22549090$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt9u0zAUxiM0xLrBIwCWuOGiCceO7SRCgMZgW6TxR1qLuLNcx2YuaVJsZ9IegNfhIXgyHLUTUiVUrhxbv-87J-c7R8lB13c6SR5jyDBg_mKZ3UilbKczAphkQDOA4l4ywWWRp4Th8iCZAOE0pRi-HiZH3i8BgOW4epAcEsJoBRVMkp9111glQ-886g0K19rJtR6CVUgbo1VAtkNn9SwFPkUSfb6WXqO6RsFZ2Y4Kid59PEHbXqbofDb__Sv9MLTBphf1l7fTUT90wWkZdIPiU4rj0-gcr35YLOOXf5jcN7L1-tH2PE7mZ-9npxfp5afz-vTkMlWMVSGlhhK9KBoCvGia3GBDFqWSREJRcbXIS4KJkZjnVBFFKTckbxotjakwVFJBfpw83_iuXf9j0D6IlfVKt63sdD94gXlRMlJxzvajgAuOGeFVRJ_toMt-cF38kWhIWMmgYDRST7bUsFjpRqydXUl3K-6yiMDLDaBc773TRigbZLB9nJ60baw4FuViKbbTFmPyAqiIyUc121HfFdine7rRGdkL-c1ZL-ZXEWAAmObAx77ebAgdk7mx2gmvrO6UbqyL4Ymmt3trvN5xUK3t4tq13_Wt9n-nJXzUiKtxb8e1xSRuLKnG2b36t8F_NPAHum_6Rw |
| CitedBy_id | crossref_primary_10_4049_jimmunol_2101076 crossref_primary_10_1097_COH_0b013e32835fd5cd crossref_primary_10_2174_1570162X17666191121114522 crossref_primary_10_1016_j_vaccine_2016_03_021 crossref_primary_10_1038_mtm_2014_7 crossref_primary_10_1371_journal_pone_0210965 crossref_primary_10_1038_s41541_024_00991_0 crossref_primary_10_3389_fimmu_2014_00417 crossref_primary_10_3389_fimmu_2019_02911 crossref_primary_10_3109_00365548_2013_871645 crossref_primary_10_1128_JVI_02165_20 crossref_primary_10_3390_v13030501 crossref_primary_10_1016_j_addr_2021_01_003 crossref_primary_10_1016_j_ymeth_2013_03_035 crossref_primary_10_3389_fimmu_2024_1478703 crossref_primary_10_18632_oncotarget_24426 crossref_primary_10_1080_08820139_2020_1867163 crossref_primary_10_1016_j_vaccine_2014_09_072 crossref_primary_10_1080_14760584_2017_1322513 crossref_primary_10_1002_iub_2107 crossref_primary_10_1186_1745_6215_15_68 crossref_primary_10_1038_s41598_017_13331_1 crossref_primary_10_18632_oncotarget_7793 crossref_primary_10_1186_s12977_016_0261_1 crossref_primary_10_1080_21645515_2017_1329070 crossref_primary_10_1080_14760584_2022_2059467 crossref_primary_10_1517_17425247_2015_1077559 crossref_primary_10_1080_21645515_2015_1021523 crossref_primary_10_1016_j_ebiom_2017_09_028 crossref_primary_10_1016_j_vaccine_2013_06_102 crossref_primary_10_4049_jimmunol_1900517 |
| Cites_doi | 10.1111/j.1600-065X.1999.tb01337.x 10.1097/QAD.0b013e32833e5009 10.1038/nature08898 10.1016/S0165-2478(01)00267-X 10.7196/SAMJ.3973 10.1053/jinf.2002.0987 10.1126/science.1100600 10.1586/14760584.3.4.S179 10.1126/science.1165706 10.1086/432014 10.1016/j.vaccine.2006.02.031 10.1016/j.vaccine.2010.12.131 10.1016/S0264-410X(01)00394-2 10.1016/j.micinf.2005.07.023 10.1089/aid.2006.22.667 10.2174/157016208785861159 10.2471/BLT.07.045294 10.1128/JVI.73.5.4404-4412.1999 10.1016/S1473-3099(10)70069-4 10.1093/infdis/jiq077 10.1002/j.1460-2075.1991.tb05010.x 10.1097/QAD.0b013e3282fdce94 10.1038/nri1107 10.1258/095646206777689035 |
| ContentType | Journal Article |
| Copyright | 2012 Elsevier Ltd Elsevier Ltd Copyright © 2012 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jun 8, 2012 |
| Copyright_xml | – notice: 2012 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2012 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jun 8, 2012 |
| DBID | FBQ AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2012.04.007 |
| DatabaseName | AGRIS CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central - New (Subscription) Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database PML(ProQuest Medical Library) Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE AGRICOLA MEDLINE - Academic Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 4054 |
| ExternalDocumentID | 3500102761 22549090 10_1016_j_vaccine_2012_04_007 US201500143060 S0264410X12005294 1_s2_0_S0264410X12005294 |
| Genre | Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | South Africa |
| GeographicLocations_xml | – name: South Africa |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK HZ~ IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG LCYCR QYZTP ABPIF ABPTK FBQ AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP AIGII APXCP CITATION CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8 ACLOT ~HD 7S9 L.6 |
| ID | FETCH-LOGICAL-c559t-4f42eb7d2067dd3f1f2b8ca2a0796cb38212fa1634c2c446f23ddeaff9109ac03 |
| IEDL.DBID | 7X7 |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Sat Sep 27 19:18:18 EDT 2025 Sun Sep 28 04:21:22 EDT 2025 Wed Aug 13 11:33:13 EDT 2025 Thu Apr 03 06:58:26 EDT 2025 Thu Apr 24 23:04:47 EDT 2025 Tue Jul 01 03:37:58 EDT 2025 Wed Dec 27 19:18:12 EST 2023 Fri Feb 23 02:31:53 EST 2024 Sun Feb 23 10:19:51 EST 2025 Tue Aug 26 17:46:16 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 27 |
| Keywords | South Africa Untreated Chronic HIV-1 Therapeutic HIV-1 vaccines |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2012 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c559t-4f42eb7d2067dd3f1f2b8ca2a0796cb38212fa1634c2c446f23ddeaff9109ac03 |
| Notes | http://dx.doi.org/10.1016/j.vaccine.2012.04.007 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 22549090 |
| PQID | 1625850754 |
| PQPubID | 105530 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1678529665 proquest_miscellaneous_1017615269 proquest_journals_1625850754 pubmed_primary_22549090 crossref_citationtrail_10_1016_j_vaccine_2012_04_007 crossref_primary_10_1016_j_vaccine_2012_04_007 fao_agris_US201500143060 elsevier_sciencedirect_doi_10_1016_j_vaccine_2012_04_007 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X12005294 elsevier_clinicalkey_doi_10_1016_j_vaccine_2012_04_007 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-06-08 |
| PublicationDateYYYYMMDD | 2012-06-08 |
| PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-08 day: 08 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2012 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Rehle, Hallett, Shisana, Pillay-van Wyk, Zuma, Carrara (bib0165) 2010; 5 Niu, Termini, Kanagavelu, Gupta, Rolland, Kulkarni (bib0075) 2011; 29 Ilves, Kivi, Ustav (bib0130) 1999; 73 Schultz, Altman, Moher (bib0145) 2010; 152 Ross, Brave, Scarlatti, Manrique, Buonaguro (bib0155) 2010; 10 Richman, Margolis, Delaney, Greene, Hazuda, Pomerantz (bib0015) 2009; 323 Krohn, Stanescu, Blasevic, Vesikari, Ranki, Ustav (bib0115) 2005; 7 Autran, Murphy, Costagliola, Tubiana, Clotet, Gatell (bib0090) 2008; 22 Department of Health (South Africa) (bib0135) 2007 Kinloch-de, Autran (bib0025) 2002; 44 Endsley, Salama, Ho (bib0095) 2008; 6 Peters (bib0030) 2001; 20 Imami, Hardy, Burton, Pires, Pido-Lopez, Moss, Gazzard, Gotch (bib0035) 2001; 79 Gotch, Hardy, Imami (bib0060) 1999; 170 Averitt (bib0105) 1999 Gotch (bib0070) 2005; 10 Gandhi, Altfeld (bib0010) 2005; 192 Pai, Tulsky, Lawrence, Colford, Reingold (bib0065) 2005 Leydon, Venter, Webster, Moleko, Osler, Barker (bib0040) 2010; 100 Xie, Lu, Samri, Costagliola, Schnuriger, da Silva (bib0150) 2010; 24 Boulle, Bock, Osler, Cohen, Channing, Hilderbrand (bib0110) 2008; 86 García, Climent, Assoumou, Gil, González, Alcamí (bib0080) 2011; 203 Virgin, Walker (bib0045) 2010; 464 Girard, Osmanov, Kieny (bib0050) 2006; 24 Department of Health (South Africa) (bib0160) 2009 Ustav, Ustav, Szymanski, Stenlund (bib0125) 1991; 10 Wahren, Liu (bib0055) 2004; 3 Blazevic, Männik, Malm, Sikut, Valtavaara, Toots (bib0120) 2006; 22 Autran, Debre, Walker, Katlama (bib0085) 2003; 3 Virgin, Walker (bib0005) 2010; 464 Autran, Carcelain, Combadiere, Debre (bib0100) 2004; 305 Dorrell (bib0020) 2006; 17 Casado, Colombo, Rauch, Martínez, Günthard, Garcia (bib0140) 2010; 5 Virgin (10.1016/j.vaccine.2012.04.007_bib0005) 2010; 464 Autran (10.1016/j.vaccine.2012.04.007_bib0090) 2008; 22 Rehle (10.1016/j.vaccine.2012.04.007_bib0165) 2010; 5 Ilves (10.1016/j.vaccine.2012.04.007_bib0130) 1999; 73 Department of Health (South Africa) (10.1016/j.vaccine.2012.04.007_bib0135) 2007 Casado (10.1016/j.vaccine.2012.04.007_bib0140) 2010; 5 Ross (10.1016/j.vaccine.2012.04.007_bib0155) 2010; 10 Peters (10.1016/j.vaccine.2012.04.007_bib0030) 2001; 20 Gotch (10.1016/j.vaccine.2012.04.007_bib0070) 2005; 10 Gandhi (10.1016/j.vaccine.2012.04.007_bib0010) 2005; 192 Gotch (10.1016/j.vaccine.2012.04.007_bib0060) 1999; 170 Girard (10.1016/j.vaccine.2012.04.007_bib0050) 2006; 24 Richman (10.1016/j.vaccine.2012.04.007_bib0015) 2009; 323 Leydon (10.1016/j.vaccine.2012.04.007_bib0040) 2010; 100 Endsley (10.1016/j.vaccine.2012.04.007_bib0095) 2008; 6 Schultz (10.1016/j.vaccine.2012.04.007_bib0145) 2010; 152 Virgin (10.1016/j.vaccine.2012.04.007_bib0045) 2010; 464 Blazevic (10.1016/j.vaccine.2012.04.007_bib0120) 2006; 22 Kinloch-de (10.1016/j.vaccine.2012.04.007_bib0025) 2002; 44 Ustav (10.1016/j.vaccine.2012.04.007_bib0125) 1991; 10 Pai (10.1016/j.vaccine.2012.04.007_bib0065) 2005 Autran (10.1016/j.vaccine.2012.04.007_bib0085) 2003; 3 Averitt (10.1016/j.vaccine.2012.04.007_bib0105) 1999 García (10.1016/j.vaccine.2012.04.007_bib0080) 2011; 203 Imami (10.1016/j.vaccine.2012.04.007_bib0035) 2001; 79 Dorrell (10.1016/j.vaccine.2012.04.007_bib0020) 2006; 17 Niu (10.1016/j.vaccine.2012.04.007_bib0075) 2011; 29 Department of Health (South Africa) (10.1016/j.vaccine.2012.04.007_bib0160) 2009 Autran (10.1016/j.vaccine.2012.04.007_bib0100) 2004; 305 Wahren (10.1016/j.vaccine.2012.04.007_bib0055) 2004; 3 Boulle (10.1016/j.vaccine.2012.04.007_bib0110) 2008; 86 Xie (10.1016/j.vaccine.2012.04.007_bib0150) 2010; 24 Krohn (10.1016/j.vaccine.2012.04.007_bib0115) 2005; 7 |
| References_xml | – year: 2009 ident: bib0160 article-title: National Antenatal Sentinel HIV & Syphilis Prevalence Survey in South Africa 2008 – start-page: 1 year: 2005 end-page: 49 ident: bib0065 article-title: Structured treatment interuptions (STI) in chronic suppressed HIV infection in adults (review) publication-title: Cochrane Database of Systematic Reviews – volume: 29 start-page: 2110 year: 2011 end-page: 2119 ident: bib0075 article-title: Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus gag antigens and conserved epitopes publication-title: Vaccine – volume: 3 start-page: 503 year: 2003 end-page: 508 ident: bib0085 article-title: Therapeutic vaccines against HIV need international partnerships publication-title: Nature Reviews Immunology – volume: 20 start-page: 688 year: 2001 end-page: 705 ident: bib0030 article-title: The basis for HIV immunotherapeutic vaccines publication-title: Vaccine – volume: 17 start-page: 436 year: 2006 end-page: 441 ident: bib0020 article-title: Therapeutic immunization for the control of HIV-1: where are we now? publication-title: International Journal of STD and AIDS – volume: 170 start-page: 173 year: 1999 end-page: 182 ident: bib0060 article-title: Therapeutic vaccines in HIV.1 infection publication-title: Immunological Reviews – volume: 305 start-page: 205 year: 2004 end-page: 208 ident: bib0100 article-title: Therapeutic vaccines for chronic infections publication-title: Science – start-page: 1 year: 1999 end-page: 2 ident: bib0105 article-title: Rebuilding the immune system publication-title: World – volume: 10 start-page: 305 year: 2010 end-page: 316 ident: bib0155 article-title: Progress towards development of an HIV vaccine: report of the AIDS vaccine 2009 Conference publication-title: Lancet Infectious Diseases – volume: 5 start-page: 1 year: 2010 end-page: 8 ident: bib0165 article-title: A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008 publication-title: PLoS One – volume: 22 start-page: 667 year: 2006 end-page: 677 ident: bib0120 article-title: Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-multiHIV DNA vaccine publication-title: AIDS Research and Human Retroviruses – volume: 3 start-page: S179 year: 2004 end-page: S188 ident: bib0055 article-title: Therapeutic vaccination against HIV publication-title: Expert Review of Vaccines – volume: 203 start-page: 473 year: 2011 end-page: 478 ident: bib0080 article-title: A therapeutic dendritic cell-based vaccine for HIV-1 infection publication-title: Journal of Infectious Diseases – volume: 10 start-page: 4321 year: 1991 end-page: 4329 ident: bib0125 article-title: Identification of the origin of replication of bovine papillomavirus and characterisation of the viral origin recognition factor E1 publication-title: EMBO Journal – volume: 100 start-page: 420 year: 2010 end-page: 424 ident: bib0040 article-title: Achieving the HIV and AIDS National Strategic Plan: a practical calculator for local target setting in district health facilities publication-title: South African Medical Journal – volume: 86 start-page: 678 year: 2008 end-page: 687 ident: bib0110 article-title: Antiretroviral therapy and early mortality in South Africa publication-title: Bulletin of the World Health Organization – volume: 152 start-page: 1 year: 2010 end-page: 11 ident: bib0145 article-title: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials publication-title: Annals of Internal Medicine – volume: 464 start-page: 224 year: 2010 end-page: 231 ident: bib0005 article-title: Immunology and the elusive AIDS vaccine publication-title: Nature – volume: 6 start-page: 401 year: 2008 end-page: 410 ident: bib0095 article-title: Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines? publication-title: Current HIV Research – volume: 24 start-page: 4062 year: 2006 end-page: 4081 ident: bib0050 article-title: A review of vaccine research and development: the human immunodeficiency virus (HIV) publication-title: Vaccine – volume: 44 start-page: 152 year: 2002 end-page: 159 ident: bib0025 article-title: HIV-1 therapeutic vaccines publication-title: Journal of Infection – volume: 22 start-page: 1313 year: 2008 end-page: 1322 ident: bib0090 article-title: Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452) publication-title: AIDS – volume: 7 start-page: 1405 year: 2005 end-page: 1413 ident: bib0115 article-title: A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A–C subtypes and the ancestor sequence of the F–H subtypes. Preclinical and clinical studies publication-title: Microbes and Infection – volume: 192 start-page: 556 year: 2005 end-page: 559 ident: bib0010 article-title: The quest for an HIV-1 therapeutic vaccine publication-title: Journal of Infectious Diseases – year: 2007 ident: bib0135 article-title: National Strategic Plan for HIV and AIDS/Comprehensive HIV and AIDS Treatment Plan Statistics Memorandum – volume: 464 start-page: 224 year: 2010 end-page: 231 ident: bib0045 article-title: Immunology and the elusive AIDS vaccine publication-title: Nature – volume: 5 start-page: 1 year: 2010 end-page: 6 ident: bib0140 article-title: Host and viral genetic correlates of clinical definitions of HIV-1 disease progression publication-title: PLoS One – volume: 79 start-page: 63 year: 2001 end-page: 76 ident: bib0035 article-title: Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination publication-title: Immunology Letters – volume: 73 start-page: 4404 year: 1999 end-page: 4412 ident: bib0130 article-title: Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which is mediated by the viral E2 protein and its binding sites publication-title: Journal of Virology – volume: 10 start-page: 48 year: 2005 end-page: 50 ident: bib0070 article-title: Therapeutic vaccines and immunotherapy revisited publication-title: Journal of HIV Therapy – volume: 323 start-page: 1304 year: 2009 end-page: 1307 ident: bib0015 article-title: The challenge of finding a cure for HIV infection publication-title: Science – volume: 24 start-page: 2323 year: 2010 end-page: 2329 ident: bib0150 article-title: Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8 cells associated with HLA-B57/5801 publication-title: AIDS – volume: 170 start-page: 173 issue: August year: 1999 ident: 10.1016/j.vaccine.2012.04.007_bib0060 article-title: Therapeutic vaccines in HIV.1 infection publication-title: Immunological Reviews doi: 10.1111/j.1600-065X.1999.tb01337.x – volume: 24 start-page: 2323 year: 2010 ident: 10.1016/j.vaccine.2012.04.007_bib0150 article-title: Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8 cells associated with HLA-B57/5801 publication-title: AIDS doi: 10.1097/QAD.0b013e32833e5009 – volume: 464 start-page: 224 issue: March year: 2010 ident: 10.1016/j.vaccine.2012.04.007_bib0005 article-title: Immunology and the elusive AIDS vaccine publication-title: Nature doi: 10.1038/nature08898 – volume: 79 start-page: 63 issue: November (1–2) year: 2001 ident: 10.1016/j.vaccine.2012.04.007_bib0035 article-title: Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination publication-title: Immunology Letters doi: 10.1016/S0165-2478(01)00267-X – volume: 100 start-page: 420 issue: July (7) year: 2010 ident: 10.1016/j.vaccine.2012.04.007_bib0040 article-title: Achieving the HIV and AIDS National Strategic Plan: a practical calculator for local target setting in district health facilities publication-title: South African Medical Journal doi: 10.7196/SAMJ.3973 – volume: 44 start-page: 152 issue: April (3) year: 2002 ident: 10.1016/j.vaccine.2012.04.007_bib0025 article-title: HIV-1 therapeutic vaccines publication-title: Journal of Infection doi: 10.1053/jinf.2002.0987 – volume: 5 start-page: 1 issue: June (6) year: 2010 ident: 10.1016/j.vaccine.2012.04.007_bib0140 article-title: Host and viral genetic correlates of clinical definitions of HIV-1 disease progression publication-title: PLoS One – year: 2007 ident: 10.1016/j.vaccine.2012.04.007_bib0135 – volume: 305 start-page: 205 issue: July (5681) year: 2004 ident: 10.1016/j.vaccine.2012.04.007_bib0100 article-title: Therapeutic vaccines for chronic infections publication-title: Science doi: 10.1126/science.1100600 – volume: 3 start-page: S179 issue: August (4 Suppl.) year: 2004 ident: 10.1016/j.vaccine.2012.04.007_bib0055 article-title: Therapeutic vaccination against HIV publication-title: Expert Review of Vaccines doi: 10.1586/14760584.3.4.S179 – volume: 5 start-page: 1 issue: June (6) year: 2010 ident: 10.1016/j.vaccine.2012.04.007_bib0165 article-title: A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008 publication-title: PLoS One – start-page: 1 issue: 4 year: 2005 ident: 10.1016/j.vaccine.2012.04.007_bib0065 article-title: Structured treatment interuptions (STI) in chronic suppressed HIV infection in adults (review) publication-title: Cochrane Database of Systematic Reviews – volume: 323 start-page: 1304 issue: March (5919) year: 2009 ident: 10.1016/j.vaccine.2012.04.007_bib0015 article-title: The challenge of finding a cure for HIV infection publication-title: Science doi: 10.1126/science.1165706 – volume: 152 start-page: 1 issue: 11 year: 2010 ident: 10.1016/j.vaccine.2012.04.007_bib0145 article-title: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials publication-title: Annals of Internal Medicine – volume: 192 start-page: 556 issue: August (4) year: 2005 ident: 10.1016/j.vaccine.2012.04.007_bib0010 article-title: The quest for an HIV-1 therapeutic vaccine publication-title: Journal of Infectious Diseases doi: 10.1086/432014 – volume: 24 start-page: 4062 issue: May (19) year: 2006 ident: 10.1016/j.vaccine.2012.04.007_bib0050 article-title: A review of vaccine research and development: the human immunodeficiency virus (HIV) publication-title: Vaccine doi: 10.1016/j.vaccine.2006.02.031 – volume: 29 start-page: 2110 issue: January year: 2011 ident: 10.1016/j.vaccine.2012.04.007_bib0075 article-title: Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus gag antigens and conserved epitopes publication-title: Vaccine doi: 10.1016/j.vaccine.2010.12.131 – start-page: 1 issue: April (96) year: 1999 ident: 10.1016/j.vaccine.2012.04.007_bib0105 article-title: Rebuilding the immune system publication-title: World – volume: 20 start-page: 688 issue: December (5–6) year: 2001 ident: 10.1016/j.vaccine.2012.04.007_bib0030 article-title: The basis for HIV immunotherapeutic vaccines publication-title: Vaccine doi: 10.1016/S0264-410X(01)00394-2 – volume: 464 start-page: 224 issue: 11 year: 2010 ident: 10.1016/j.vaccine.2012.04.007_bib0045 article-title: Immunology and the elusive AIDS vaccine publication-title: Nature doi: 10.1038/nature08898 – volume: 7 start-page: 1405 issue: 14 year: 2005 ident: 10.1016/j.vaccine.2012.04.007_bib0115 article-title: A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A–C subtypes and the ancestor sequence of the F–H subtypes. Preclinical and clinical studies publication-title: Microbes and Infection doi: 10.1016/j.micinf.2005.07.023 – volume: 22 start-page: 667 issue: July (7) year: 2006 ident: 10.1016/j.vaccine.2012.04.007_bib0120 article-title: Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-multiHIV DNA vaccine publication-title: AIDS Research and Human Retroviruses doi: 10.1089/aid.2006.22.667 – volume: 10 start-page: 48 issue: September (3) year: 2005 ident: 10.1016/j.vaccine.2012.04.007_bib0070 article-title: Therapeutic vaccines and immunotherapy revisited publication-title: Journal of HIV Therapy – year: 2009 ident: 10.1016/j.vaccine.2012.04.007_bib0160 – volume: 6 start-page: 401 issue: September (5) year: 2008 ident: 10.1016/j.vaccine.2012.04.007_bib0095 article-title: Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines? publication-title: Current HIV Research doi: 10.2174/157016208785861159 – volume: 86 start-page: 678 issue: 9 year: 2008 ident: 10.1016/j.vaccine.2012.04.007_bib0110 article-title: Antiretroviral therapy and early mortality in South Africa publication-title: Bulletin of the World Health Organization doi: 10.2471/BLT.07.045294 – volume: 73 start-page: 4404 year: 1999 ident: 10.1016/j.vaccine.2012.04.007_bib0130 article-title: Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which is mediated by the viral E2 protein and its binding sites publication-title: Journal of Virology doi: 10.1128/JVI.73.5.4404-4412.1999 – volume: 10 start-page: 305 issue: May (5) year: 2010 ident: 10.1016/j.vaccine.2012.04.007_bib0155 article-title: Progress towards development of an HIV vaccine: report of the AIDS vaccine 2009 Conference publication-title: Lancet Infectious Diseases doi: 10.1016/S1473-3099(10)70069-4 – volume: 203 start-page: 473 issue: February year: 2011 ident: 10.1016/j.vaccine.2012.04.007_bib0080 article-title: A therapeutic dendritic cell-based vaccine for HIV-1 infection publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/jiq077 – volume: 10 start-page: 4321 year: 1991 ident: 10.1016/j.vaccine.2012.04.007_bib0125 article-title: Identification of the origin of replication of bovine papillomavirus and characterisation of the viral origin recognition factor E1 publication-title: EMBO Journal doi: 10.1002/j.1460-2075.1991.tb05010.x – volume: 22 start-page: 1313 issue: July (11) year: 2008 ident: 10.1016/j.vaccine.2012.04.007_bib0090 article-title: Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452) publication-title: AIDS doi: 10.1097/QAD.0b013e3282fdce94 – volume: 3 start-page: 503 issue: June (6) year: 2003 ident: 10.1016/j.vaccine.2012.04.007_bib0085 article-title: Therapeutic vaccines against HIV need international partnerships publication-title: Nature Reviews Immunology doi: 10.1038/nri1107 – volume: 17 start-page: 436 issue: July (7) year: 2006 ident: 10.1016/j.vaccine.2012.04.007_bib0020 article-title: Therapeutic immunization for the control of HIV-1: where are we now? publication-title: International Journal of STD and AIDS doi: 10.1258/095646206777689035 |
| SSID | ssj0005319 |
| Score | 2.2114568 |
| Snippet | ► FIT GTU®-multi-HIVB was the first therapeutic HIV-1 vaccine trial conducted in South Africa. ► This plasmid DNA vaccine is safe and well-tolerated in HIV-1... Highlights► FIT GTU ®-multi-HIVB was the first therapeutic HIV-1 vaccine trial conducted in South Africa. ► This plasmid DNA vaccine is safe and well-tolerated... BACKGROUND: Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming... Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a... Highlights * FIT GTU®-multi-HIVB was the first therapeutic HIV-1 vaccine trial conducted in South Africa. * This plasmid DNA vaccine is safe and well-tolerated... |
| SourceID | proquest pubmed crossref fao elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4046 |
| SubjectTerms | Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - therapy Acquired Immunodeficiency Syndrome - virology Adult adults AIDS AIDS Vaccines - administration & dosage AIDS Vaccines - adverse effects AIDS Vaccines - immunology Allergy and Immunology antiretroviral agents Antiretroviral drugs CD4 Lymphocyte Count CD4-positive T-lymphocytes CD8-positive T-lymphocytes Chronic HIV-1 cytokines Deoxyribonucleic acid disease course DNA Drug-Related Side Effects and Adverse Reactions - epidemiology Female genes Genotype haplotypes HIV HIV infections HIV-1 - classification HIV-1 - genetics HIV-1 - isolation & purification Human immunodeficiency virus Human immunodeficiency virus 1 Humans immune response immunization Immunotherapy - methods Injections, Intradermal Injections, Intramuscular Male monitoring morbidity mortality Placebos - administration & dosage plasmids Plasmids - administration & dosage recombinant DNA recombinant vaccines RNA, Viral - blood screening South Africa Therapeutic HIV-1 vaccines Treatment Outcome Untreated Vaccines Vaccines, DNA - administration & dosage Vaccines, DNA - adverse effects Vaccines, DNA - immunology Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - adverse effects Vaccines, Synthetic - immunology Viral Load Young Adult |
| SummonAdditionalLinks | – databaseName: ScienceDirect Freedom Collection 2013 dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELfGJBAvCMqfBQYyEtpT3TqOkyaPY1BapE2T1k59sxzHnjqhdCLtpL3sja_Dh-CTceck7RCMIR7j-urEPt-dfXe_I-RdEhqbajNgmQXzTdrYstwlBQtdZvMCGm2ICc6HR8loKj_P4tkWOWhzYTCsspH9tUz30rpp6Tez2b-Yz_sn3OtyPgs9eFCGmKCI_gU83bu-EeYR-eIe2Jlh700WT_-8d6kNuq8xwkv0ahzt2_TTPacXt1uhXhsNH5NHjRlJ9-s3fUK2bNkh9-vCklcd8uCwcZl3yN5xDU591aWTTa5V1aV79HgDWw00nVOMjPHpubQlf0q-jUv05GBNHrpw9Ea6Fq1DQei8pMPxhPGkSzX-ZWXpeEx9NRCk0PTD0T5tpqBLP02mP74zn_bLRuPT912kX5U-3t0WFJpYSOsIMXisVjneE1XPyHT4cXIwYk3pBmbgiLJk0klh80GB4PBFEbnQiTw1Wmg-yBKTRyloTKfBFpRGGFg1JyKQs9o5sF4ybXj0nGyXi9LuECp0KgsRA7PFhSwikRsbSxtpy3MrUxMFRLYLpkyDa47lNb6oNoDtXDUfqXCdFZcK1jkgvTXZRQ3scRdB0nKDarNWQc4qUD13EQ7-RGirRlpUKlQVdFa_cXRA0jXlL5viXwbdAYZV-gxUhZqeCLzYQihHnvCA7LZcrDavAOfgFM4GMQz6dv0ziBr0H-nSLlYVjjYAA1gk2V_6gPGDrvwkDsiLeoesp1fgZQTP-Mv__6xX5CE--Vi9dJdsL7-u7GuwCpf5G7_tfwJpVVyz priority: 102 providerName: Elsevier |
| Title | Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU®-Multi-HIVB, in untreated HIV-1 infected subjects |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X12005294 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X12005294 https://dx.doi.org/10.1016/j.vaccine.2012.04.007 https://www.ncbi.nlm.nih.gov/pubmed/22549090 https://www.proquest.com/docview/1625850754 https://www.proquest.com/docview/1017615269 https://www.proquest.com/docview/1678529665 |
| Volume | 30 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect Freedom Collection Journals customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: ACRLP dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIKHN dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2013 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AKRWK dateStart: 19831201 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF6RViAuCAK0hlItEuopm67X69epSktDDGoU0aTKbbVerxEVcto6QeqFEz-cGT8SDrTlEie2J37s7My38yTkQ-AaG2kTstgCfJPWtyzNg4y5eWzTDHZaFxOcz8bBaCY_z_15Y3Arm7DKViZWgjpbGLSRH7oA1CMAL748urpm2DUKvatNC40O2XYBqiBXh_NwE-LhVY09YJkhmXT5fJPBc3jZ_6kNuq4xukv06xrad-mmTq4XdyPQShMNn5NnDYSkg3rMX5BHtuiSx3VTydsueXLWuMu75GBSF6a-7dHpJs-q7NEDOtmUrAaa7gVGxVSpubQlf0l-JwV6cbAfD13k9K9ULVqHgdDvBR0mU8aDHtX4l6WlSUKrTiBIoenH8YA2r6BHP01nR6zK-GWj5OK4h-Srogp1txmFXcyldXAY_CxXKZqIyldkNjydnoxY07WBGVidLJnMpbBpmGFd-CzzcjcXaWS00DyMA5N6ESjLXAMMlEYYWIzmwgMRq_McgEusDfdek61iUdhdQoWOZCZ84DM_k5knUmN9aT1teWplZDyHyHa8lGlKmmNnjR-qjV27VM0zKhxmxaWCYXZIf012Vdf0eIggaJlBtQmrIGIVaJ2HCMN_EdqyERSlclUJJ6tzXgFTPnerSlixdEi0pmywUI1x_ueiu8CvSn8DLaFm5wJtWljFkQfcIXstE6vNLaxnlkPerw-DlEHXkS7sYlXi1ULAviKI7zkHcA968QPfITv1BFm_XoF2CB7zN_ffwFvyFB-kCsWL9sjW8mZl3wHoW6b7pNP_5e5X8xs-oxP4vj1IvozGsD0-HU--_gE1_VZY |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF61RTwuCMKjhgKLBD1l0_V6_TqgqlBCTJuqUpMqt2W9XiMq5BScgHLn9_AbmfEj4UBbLj3G8fg1s7Pf7nwzQ8irwDU20iZksQX4Jq1vWZoHGXPz2KYZHLQuJjgPj4LBWH6c-JM18rvNhUFaZesTK0edTQ3uke-4ANQjAC--3D3_xrBrFEZX2xYatVkc2MVPWLKVb5J90O9rIfrvR-8GrOkqwAyg5xmTuRQ2DTOsW55lXu7mIo2MFpqHcWBSLwJnnmuAKdIIA4ulXHjgAnSew8Qaa8M9uO46uSE9LrFWfzgJV5QSr2okAssayaTLJ6uMoZ2z3g9tMFSObDLRq2t2XzQXrud6ejHirWa-_j1yt4GsdK-2sftkzRYdcrNuYrnokFvDJjzfIdvHdSHsRZeOVnldZZdu0-NViWyQ6ZwiC6dKBaat-APyKykwaoT9f-g0p3-lhtGadkK_FLSfjBgPulTjJUtLk4RWnUdQQtP9oz3afIIu_TAa77Iqw5gNktO3XRSfFxW13mYUDjGX1mQ0-FnOU9ySKh-S8bXo8xHZKKaF3SRU6Ehmwge79jOZeSI11pfW05anVkbGc4hs9aVMU0IdO3l8VS1X7kw176hQzYpLBWp2SG8pdl7XELlKIGiNQbUJsuDSFcxyVwmG_xK0ZeOYSuWqEk5WJ7wCwnziVpW3YumQaCnZYK8aU_3PTTfBXpX-DLOSGp8I3EPDqpE84A7Zao1YrR5hOZId8nL5N3g1DFXpwk7nJd4tBKwtgviScwBnIWsg8B3yuB4gy88rcN-Dx_zJ5Q_wgtwejIaH6jA5OnhK7uBLVTTAaItszL7P7TMAnLP0eTXKKfl03W7lD7ffjwc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELbaIiouCMKjgQJGgp7ixOv1vg6oKoSQpTSq1KTKzfV6vYgKbQqbgHLnV_HrmNlHwoG2XHrMZmdfMx5_9nwzQ8gr3zE21CZgkQX4Jq1nWZL5KXOyyCYpHLQOJjgfjfzhRH6cetMN8rvJhUFaZeMTS0edzgzukfccAOohgBdP9rKaFnHcH-xffGPYQQojrU07jcpEDu3yJyzfijdxH3T9WojB-_G7Ias7DDADSHrOZCaFTYIUa5inqZs5mUhCo4XmQeSbxA3BsWcaIIs0wsDCKRMuuAOdZTDJRtpwF667SW4FrnSRThZMgzW9xC2bisASRzLp8Ok6e6h33v2hDYbNkVkmulX97svmxc1Mzy5Hv-UsOLhH7tbwlR5U9nafbNi8RW5XDS2XLbJ9VIfqW2TvuCqKvezQ8TrHq-jQPXq8LpcNMq1TZOSUacG0EX9AfsU5RpCwFxCdZfSvNDFaUVDol5wO4jHjfodqvGRhaRzTsgsJSmjaHx3Q-hN06IfxZJ-V2cZsGJ--7aD4Ii9p9jalcIg5tCKmwc9ikeD2VPGQTG5En4_IVj7L7Q6hQocyFR7YuJfK1BWJsZ60rrY8sTI0bpvIRl_K1OXUsavHV9Xw5s5V_Y4K1ay4VKDmNumuxC6qeiLXCfiNMagmWRbcu4IZ7zrB4F-CtqidVKEcVcDJ6oSXoJhPnbIKVyTbJFxJ1jiswlf_c9MdsFelP8MMpSYnAvfTsIIk93mb7DZGrNaPsBrVbfJy9Td4OAxb6dzOFgXeLQDcLfzoinMAcyGDwPfa5HE1QFafV-AeCI_4k6sf4AXZBoeiPsWjw6fkDr5TyQgMd8nW_PvCPgPsOU-el4OckrOb9ip_ANCck0I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Indicators+of+therapeutic+effect+in+FIT-06%2C+a+Phase+II+trial+of+a+DNA+vaccine%2C+GTU%3F-Multi-HIVB%2C+in+untreated+HIV-1+infected+subjects&rft.jtitle=Vaccine&rft.au=Vardas%2C+Eftyhia&rft.au=Stanescu%2C+Ioana&rft.au=Leinonen%2C+Mika&rft.au=Ellefsen%2C+Kim&rft.date=2012-06-08&rft.pub=Elsevier+Limited&rft.issn=0264-410X&rft.eissn=1873-2518&rft.volume=30&rft.issue=27&rft.spage=4046&rft_id=info:doi/10.1016%2Fj.vaccine.2012.04.007&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3500102761 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X12X00264%2Fcov150h.gif |